Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Tuesday 29th June 2021

8:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST

Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and several FDA approved products currently on the market. There has been tremendous effort to make CAR T cells more effective, safe, and persistent when treating patients. On the manufacturing side, however, errors, lot-to-lot variation, and contamination can be associated with open processes and manual handling of CAR T cells.

In this talk, we will discuss a closed cell therapy manufacturing workflow developed by Thermo Fisher Scientific. This GMP compliant, semi-automated manufacturing platform, which when used in combination with Gibco™ Cell Therapy System™ (CTS™) reagents, protocols, and analytics, can result in efficient, consistent, regulatory-compliant manufacture of CAR T cell product. Taken together with instrument modularity, digital connectivity, and cGMP compatibility, the manufacturing of therapeutic CAR T cells using this workflow will help enable a lower rate of contamination, less product failure, and higher product consistency.

Please join us to learn more about this workflow that combines the Gibco CTS Rotea Counterflow Centrifugation System with the CTS LV-MAX Lentiviral Production System, CTS Dynabeads, the HyPerforma™ Rocker Bioreactor, HyPerforma™ G3Lab™ Controller, and the CryoMed Controlled Rate Freezer for the manufacture of CAR T cells for clinical use.

Attendees will:

  • Consider the various systems needed to develop and manufacture CAR T cell therapies, and solutions for mitigating the possibility of contamination, variability, and human error
  • Understand the benefits of implementing closed, GMP-compliant, digitally connected solutions at earlier stages in CAR T cell therapy development
  • Learn about the various modular solutions that Thermo Fisher Scientific can provide to assist in the implementation of a CAR T cell therapy manufacturing process


Sponsored by Thermo Fisher Scientific





Presenter
Yongchang Ji, PhD
Manager of Product Applications, Cell and Gene Therapy Group
Thermo Fisher Scientific
View Biography
Presenter
Semsi Ensari, PhD
Senior Director
Kite Pharma
View Biography
Presenter
Nathan Moore, PhD
Associate Director, Engineering & Automation Cell Therapies, Pharmaceutical Sciences
Takeda
Presenter
Elisa Manzotti
CEO and Founder
BioInsights Publishing
View Biography
Presenter
Jennie OSullivan
Webinar Manager
BioInsights
Presenter
Client
Support

Presenter
Client Support 2


Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

Submit